The change in CIMT from baseline to 12 months was 0.044 mm in the placebo group (P<0.001) and 0.014 mm in the ER-niacin group (P=0.023). Thus, the increase in CIMT was 3-fold greater in the placebo than in the ER-niacin group.

There was a trend towards significance for the between-group comparison of the rate of progression for the placebo and ER-niacin groups (P=0.08).

Taylor AJ, et al. ARBITER 2: A double-blind, placebo-controlled study of extended-release niacin on Atherosclerosis progression in secondary prevention patients treated with statins.